IFIT1: A Protein Targeted for Drug and Biomarker Development (G3434)

Target Name: IFIT1

NCBI ID: G3434

IFIT1

IFIT1: A Protein Targeted for Drug and Biomarker Development

IFIT1 (GARG-16) is a protein that is expressed in various tissues throughout the body, including the brain, heart, and kidneys. It is a member of the IFIT family, which includes a variety of proteins that are involved in the regulation of various cellular processes. One of the most interesting aspects of IFIT1 is its potential as a drug target or biomarker.

IFIT1 has been shown to play a role in a number of important cellular processes. For example, it has been shown to be involved in the regulation of cell division and growth, as well as in the regulation of ion and water transport. Additionally, IFIT1 has been shown to play a role in the regulation of cellular signaling pathways, including the TGF-β pathway. This pathway is involved in the regulation of cell growth, differentiation, and survival, and is a key factor in the development and progression of many diseases, including cancer.

Given the important role that IFIT1 plays in cellular processes, it is a potential drug target or biomarker that could be targeted by small molecules or other therapeutic agents. One approach to targeting IFIT1 is to use small molecules that can modulate its activity. This could involve using drugs that interact with specific regions of the IFIT1 protein, such as the N-terminus or the C-terminus. Alternatively, it could involve using drugs that modulate the activity of other proteins that interact with IFIT1, such as the TGF-β pathway.

Another approach to targeting IFIT1 is to use antibodies that are specific for it. This could involve using antibodies that recognize specific epitopes or domains within the IFIT1 protein, and then using these antibodies to block or inhibit its activity. This approach has the advantage of being highly specific, and can be useful for targeting IFIT1 in a specific and targeted way.

In addition to its potential as a drug target or biomarker, IFIT1 is also of interest as a potential biomarker for certain diseases. For example, it has been shown to be involved in the regulation of cellular processes that are altered in a variety of diseases, including cancer. This suggests that IFIT1 may be a useful biomarker for certain types of cancer, such as breast, ovarian, or prostate cancer.

Overall, IFIT1 is a protein that has the potential to be a drug target or biomarker for a variety of diseases. Further research is needed to fully understand its role and to develop effective therapies that can target it.

Protein Name: Interferon Induced Protein With Tetratricopeptide Repeats 1

Functions: Interferon-induced antiviral RNA-binding protein that specifically binds single-stranded RNA bearing a 5'-triphosphate group (PPP-RNA), thereby acting as a sensor of viral single-stranded RNAs and inhibiting expression of viral messenger RNAs. Single-stranded PPP-RNAs, which lack 2'-O-methylation of the 5' cap and bear a 5'-triphosphate group instead, are specific from viruses, providing a molecular signature to distinguish between self and non-self mRNAs by the host during viral infection. Directly binds PPP-RNA in a non-sequence-specific manner. Viruses evolved several ways to evade this restriction system such as encoding their own 2'-O-methylase for their mRNAs or by stealing host cap containing the 2'-O-methylation (cap snatching mechanism). Exhibits antiviral activity against several viruses including human papilloma and hepatitis C viruses

The "IFIT1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about IFIT1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets